Results 51 to 60 of about 36,119 (263)

Synergistic effect between denosumab and immune checkpoint inhibitors (ICI)? A retrospective study of 268 patients with ICI and bone metastases

Journal of Bone Oncology
Background: Bone metastasis is a significant concern in advanced solid tumors, contributing to diminished patient survival and quality of life due to skeletal-related events (SREs). Denosumab (DMAB), a monoclonal antibody targeting the receptor activator
E. Mabrut, S. Mainbourg, J. Peron, D. Maillet, S. Dalle, C. Fontaine Delaruelle, E. Grolleau, P. Clezardin, E. Bonnelye, C.B. Confavreux, E. Massy   +10 more
doaj   +1 more source

Activity of eribulin mesylate in brain metastasis from breast cancer. a stone in a pond? [PDF]

, 2018
Background: Brain metastases develop in approximately 10-25% of patients with metastatic breast cancer (MBC) and are associated with a very poor prognosis.
Catania, G., Cognetti, F., Fabi, A., Gasparro, S., Malaguti, P., Vidiri, A.   +5 more
core   +1 more source

2D copper nanozyme patches facilitate bone regeneration via interfacial modulation of osteoclast‐osteoblast dynamics

BMEMat, EarlyView.
This study develops a nano‐enzyme patch (ezPatch) targeting bone interfaces. Utilizing ligand‐to‐metal charge transfer (LMCT) catalysis and bone‐targeting ligands on copper nanosheets, ezPatch simultaneously scavenges reactive oxygen species (ROS) and generates oxygen in situ at bone‐losing sites.
Yi Chen, Haoyue Hu, Danyang Wang, Ying Wang, Zhibang Li, Xiaoyi Liu, Yandi Zhang, Junkun Feng, Weiwei Zhao, Kai Li, Qi‐Zhi Zhong, Shaohua Ge, Jianhua Li   +12 more
wiley   +1 more source

Measuring the Impact of the Substitution of Innovator Biologics With Biosimilars on Uptake and Costs Among Ontario Public Drug Benefit Recipients

Clinical Pharmacology &Therapeutics, EarlyView.
In Ontario, biologics have historically represented a small proportion of public drug claims but a large proportion of spending. Biosimilars, lower cost alternatives to biologics, offer a potential solution to the rising spending on biologics. From March 2023 to January 2024, the Ontario Ministry of Health required public drug program beneficiaries on ...
Anita Iacono, Martin K. H. Ho, Joanna Yang, Tonya Campbell, William Wynne, Dana Shearer, Lene Andersen, Eric Majer, Shaleesa Ledlie, Mina Tadrous, Tara Gomes   +10 more
wiley   +1 more source

Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review

BMC Cancer, 2019
Background While denosumab has been shown to prevent skeletal-related events in patients with bone metastasis, there is a concern that it may cause atypical femoral fracture (AFF).
Momoko Takahashi, Yukinori Ozaki, Rika Kizawa, Jun Masuda, Kentaro Sakamaki, Keiichi Kinowaki, Taro Umezu, Chihiro Kondoh, Yuko Tanabe, Nobuko Tamura, Yuji Miura, Takashi Shigekawa, Hidetaka Kawabata, Noriyuki Baba, Haruo Iguchi, Toshimi Takano   +15 more
doaj   +1 more source

Objective response of denosumab for multiple pulmonary metastases from giant cell tumor of bone: A case report and review of the literature

Current Problems in Cancer: Case Reports, 2021
A 23-year-old man received denosumab therapy for histologically proven multiple pulmonary metastases from a giant cell tumor of the distal femur after surgery.
Ikuo Kudawara, Shigeki Kakunaga, Koji Takami   +2 more
doaj   +1 more source

Denosumab rapidly increases cortical bone in key locations of the femur: a 3D bone mapping study in women with osteoporosis. [PDF]

, 2014
Women with osteoporosis treated for 36 months with twice-yearly injections of denosumab sustained fewer hip fractures compared with placebo. Treatment might improve femoral bone at locations where fractures typically occur.
Brown, Jacques P, Gee, Andrew H, Libanati, Cesar, McClung, Michael R, Poole, Kenneth ES, Treece, Graham M, Wang, Andrea   +6 more
core   +2 more sources

Impact of Denosumab Adherence on Renal Function and Mortality Rates in Type 2 Diabetes Patients With Osteoporosis

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Type 2 diabetes mellitus (T2DM) is associated with an increased risk of osteoporosis and fractures, and denosumab, a non‐kidney‐excreted antiresorptive medication, represents a viable alternative to bisphosphonates for osteoporosis treatment in patients with T2DM. This study aimed to investigate the association among denosumab adherence, renal
Yu‐Chuan Chang, Jian‐Chih Chen, Sung‐Yen Lin, Kun‐Der Lin, Pei‐Shan Ho, Chung‐Hwan Chen, Yin‐Chih Fu, Tien‐Ching Lee   +7 more
wiley   +1 more source

Two Cases of Sarcoma Arising in Giant Cell Tumor of Bone Treated with Denosumab

Case Reports in Medicine, 2015
Giant cell tumor (GCT) of bone is a generally benign, but often locally aggressive, neoplasm of bone, with a propensity for recurrence. Sarcomatous transformation is rare and typically occurs with a history of recurrences and radiation treatment ...
Cory Julian Broehm, Erika L. Garbrecht, Jeff Wood, Therese Bocklage   +3 more
doaj   +1 more source

Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases

Bone Reports, 2022
Denosumab is a commonly used antiresorptive treatment in patients with osteoporosis or solid tumours with bone metastases. Upon denosumab discontinuation, a rebound phenomenon can occur that results in an increased (vertebral) fracture risk.
Jolan Dupont, Wesley Appermans, Marian Dejaeger, Isabelle Wauters, Michaël R. Laurent, Evelien Gielen   +5 more
doaj   +1 more source